Drugs / CMV-Peptide-Specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00674648 | Aug 2007 → Mar 2014 | cytomegalovirus infection | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV-Peptide-Specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00674648 ↗ |
| Modality | Cell therapy | “CMV-pp65 peptide-specific T cell lines, generated in vitro” NCT00674648 ↗ |